Dr. Reddy’s Announces the Appointment of New Chief Financial Officer (CFO) and Head for North America Business

  Dr. Reddy’s Announces the Appointment of New Chief Financial Officer (CFO)
  and Head for North America Business

Business Wire

HYDERABAD, India -- November 27, 2012

Dr. Reddy’s Laboratories Ltd. (NYSE: RDY) today announced that Umang Vohra,
who was the CFO of the company for the past four years, will take over the
role of Executive Vice-President and Head of North America Generics Business
from January 2013.

Subsequently, Saumen Chakraborty has been appointed as the CFO of the company
effective 2 January, 2013. Saumen is currently the President and Global Head
of Quality, HR and IT & Business Process Excellence (BPE) at Dr. Reddy’s. He
was also the CFO of Dr. Reddy’s between 2006 and 2008.


This press release includes forward-looking statements, as defined in the U.S.
Private Securities Litigation Reform Act of 1995. We have based these
forward-looking statements on our current expectations and projections about
future events. Such statements involve known and unknown risks, uncertainties
and other factors that may cause actual results to differ materially. Such
factors include, but are not limited to, changes in local and global economic
conditions, our ability to successfully implement our strategy, the market
acceptance of and demand for our products, our growth and expansion,
technological change and our exposure to market risks. By their nature, these
expectations and projections are only estimates and could be materially
different from actual results in the future.

About Dr. Reddy’s

Dr. Reddy’s Laboratories Ltd. (NYSE: RDY) is an integrated global
pharmaceutical company, committed to providing affordable and innovative
medicines for healthier lives. Through its three businesses - Pharmaceutical
Services and Active Ingredients, Global Generics and Proprietary Products –
Dr. Reddy’s offers a portfolio of products and services including APIs, custom
pharmaceutical services, generics, biosimilars, differentiated formulations
and NCEs. Therapeutic focus is on gastro-intestinal, cardiovascular,
diabetology, oncology, pain management, anti-infective and pediatrics. Major
markets include India, USA, Russia and CIS, Germany, UK, Venezuela, S. Africa,
Romania, and New Zealand. For more information, log on to: www.drreddys.com.


Dr. Reddy’s Laboratories Ltd.
Investors and Financial Analysts:
Kedar Upadhye, +91-40-66834297
Saunak Savla, +91-40-49002135
Milan Kalawadia (USA), +1 908-203-4931
S Rajan, +91-40-49002445
Press spacebar to pause and continue. Press esc to stop.